Trade Report: The PBWM Holdings LLC reaches $403,000 position of Pfizer Inc. (PFE)

The PBWM Holdings LLC reaches $403,000 position  of Pfizer Inc. (PFE)

PBWM Holdings LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 20.1% during the second quarter, Holdings Channel reports. The fund owned 11,434 shares of the biopharmaceutical company’s stock after selling 2,877 shares during the period. PBWM Holdings LLC’s holdings in Pfizer were worth $403,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. P.R. Herzig & Co. Inc. increased its position in shares of Pfizer by 7.9% in the first quarter. P.R. Herzig & Co. Inc. now owns 36,800 shares of the biopharmaceutical company’s stock valued at $1,091,000 after buying an additional 2,700 shares during the period. Davis R M Inc. increased its position in shares of Pfizer by 9.0% in the first quarter. Davis R M Inc. now owns 65,417 shares of the biopharmaceutical company’s stock valued at $1,939,000 after buying an additional 5,425 shares during the period. Sigma Planning Corp increased its position in shares of Pfizer by 9.9% in the first quarter. Sigma Planning Corp now owns 88,504 shares of the biopharmaceutical company’s stock valued at $2,623,000 after buying an additional 7,972 shares during the period. Private Trust Co. NA increased its position in shares of Pfizer by 2.5% in the first quarter. Private Trust Co. NA now owns 114,956 shares of the biopharmaceutical company’s stock valued at $3,406,000 after buying an additional 2,776 shares during the period. Finally, Traynor Capital Management Inc. increased its position in shares of Pfizer by 0.9% in the first quarter. Traynor Capital Management Inc. now owns 27,790 shares of the biopharmaceutical company’s stock valued at $823,000 after buying an additional 254 shares during the period. 69.66% of the stock is owned by institutional investors and hedge funds.

Pfizer Inc. (NYSE:PFE) traded down 0.305% on Wednesday, hitting $33.029. The stock had a trading volume of 4,825,363 shares. The stock’s 50 day moving average is $34.20 and its 200 day moving average is $34.27. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39. The stock has a market cap of $200.34 billion, a price-to-earnings ratio of 29.281 and a beta of 0.86.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same quarter in the prior year, the company posted $0.56 earnings per share. Pfizer’s quarterly revenue was up 10.9% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post $2.46 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 3.62%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio is presently 95.24%.

PFE has been the topic of several research reports. Vetr upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price target on the stock in a report on Monday, June 27th. Deutsche Bank AG reiterated a “buy” rating and issued a $44.00 price target on shares of Pfizer in a report on Thursday, August 18th. Credit Suisse Group AG reiterated an “outperform” rating and issued a $40.00 price target on shares of Pfizer in a report on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, August 23rd. Finally, Jefferies Group set a $41.50 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Thursday, July 14th. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $38.78.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Related posts

Leave a Comment